Relationship between clinical features of Parkinson's disease and presynaptic dopamine transporter binding assessed with [123I]IPT and single-photon emission tomography

European Journal of Nuclear Medicine

Volumn 24, Issue 4, 1997, Pages 415-421

  Tatsch, Klaus ^a,e   Schwarz, Johannes ^a,c   Mozley, P David ^b   Linke, Rainer ^a   Pogarell, Oliver ^a,d   Oertel, Wolfgang H ^a,d   Fieber, Ruth S ^a   Hahn, Klaus ^a   Kung, Hank F ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF ULM   (Germany)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Cocaine analogues; Dopamine transporter; Parkinson's disease; Single photon emission tomography

Indexed keywords

COCAINE DERIVATIVE; DOPAMINE TRANSPORTER; IODINE 123; N (3 IODOPROPEN 2 YL) 2BETA CARBOMETHOXY 3BETA (4 CHLOROPHENYL)TROPANE; PRESYNAPTIC RECEPTOR; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; CAMERA; CAUDATE NUCLEUS; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE DURATION; DOSE TIME EFFECT RELATION; DRUG MIXTURE; HUMAN; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PUTAMEN; RECEPTOR BINDING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0030935431     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00881814     Document Type: Article

References (38)

1. Koller WC, Langston JW, Hubble JP, et al. Does a long preclinical period occur in Parkinson's disease? Neurology 1991; 41 Suppl 2: 8-13.
2. McGeer PL, Itagaki S, Akiyama S, McGeer EG. Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 1988; 24: 574-576.
3. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967; 17: 427-442.
4. Leenders KL, Salmon EP, Tyrell P, Perani D, Brooks DJ, Sager H, Jones T, Marsden D, Frackowiak RSJ. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990; 47: 1290-1298.
5. 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990; 28: 547-555.
6. Sawle GV. The detection of preclinical Parkinson's disease: what is the role of positron emission tomography? Mov Disord 1993; 8: 271-277.
7. 18F-DOPA and positron emission tomography. Neurology 1992; 42: 1894-1900.
8. 11C]WIN 35,428. Synapse 1993; 15: 130-142.
9. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993; 34: 423-431.
10. Innis RB, Reibyl JP, Scanley BE, Laruelle M, Abi-Dargham A, Wallace E, Baldwin RM, Zea-Ponce Y, Zoghbi S, Wang S, Gao Y, Neumeyer JL, Charney DS, Hoffer PB, Marek KL. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson's disease. Proc Natl Acad Sci USA 1993; 90: 11965-11969.
11. Brücke T, Kornhuber J, Angelberger P, Asenbaum S, Frassine H, Podreka I. SPECT imaging of dopamine and serotonin transporters with [I-123]β-CIT. Binding kinetics in the human brain. J Neural Transm 1993; 94: 137-146.
12. Kuikka JT, Bergström KA, Vanninen E, Laulumaa V, Hartikainen P, Länsimies E. Initial experience with single-photon emission tomography using iodine-123-labelled 2β-carbomethoxy-3β-(4-iodophenyl)tropane in human brain. Eur J Nucl Med 1993; 20: 783-786.
13. Innis RB. Single-photon emission tomography imaging of dopamine terminal innervation: a potential clinical tool in Parkinson's disease. Eur J Nucl Med 1994; 21: 1-5.
14. Volkow ND, Ding Y-S, Fowler JS, Wang GJ, Logan J, Gatley SJ, Schlyer DJ, Pappas N. A new PET ligand for the dopamine transporter: studies in the human brain. J Nucl Med 1995; 36: 2162-2168.
15. 123I]β-CIT SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996; 46: 231-237.
16. Giros B, Caron MG. Molecular characterization of the dopamine transporter. Trends Pharm Sci 1993; 14: 43-49.
17. Nirenberg MJ, Vaughan RA, Uhl GR, Kuhar MJ, Pickel VM. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J Neurosci 1996; 16: 436-447.
18. Lundkvist C, Halldin C; Swahn CG, Hall H, Karlsson P, Nakashima Y, Wang S, Millius RA, Neumeyer JL, Farde L. [O-methyl-11-C]β-CIT-FP, a potential radioligand for quantitation of the dopamine transporter: preparation, autoradiography, metabolite studies, and positron emission tomography examinations. Nucl Med Biol 1995; 22: 905-913.
19. Laihinen AO, Rinne JO, Nagren KA, Lehikoinen PK, Pikonen VJ, Ruotsalainen UH, Ruottinen HM, Rinne UK. PET studises on brain monoamine transporters with carbon-11-β-CIT in Parkinson's disease. J Nucl Med 1995; 36: 1263-1267.
20. 11C]β-CIT binding to monoamine transporters in the monkey and human brain. Synapse 1994; 16: 93-103.
21. Goodman MM, Kung M-P, Kabalka GW, Kung HF, Switzer R. Synthesis and characterization of radioiodinated N-(3-iodopropen-1-yl)-2β-carbomethoxy-3β-(4-chlorophenyl)tropanes: potential dopamine reuptake site imaging agents. J Med Chem 1994; 37: 1535-1542.
22. Carroll FI, Kotian P, Dehghani A, Gray JL, Kuzemko MA, Parham KA, Abraham P, Lewin AH, Boja JW, Kuhar MJ. Cocaine and 3β-(4-substituted phenyl)tropane-2β-carboxylic acid ester and amide analogues. New high-affinity and selective compounds for the dopamine transporter. J Med Chem 1995; 38: 379-388.
23. Seibyl JP, Wallace E, Smith EO, Stabin M, Baldwin RM, Zoghbi S, Zea-Ponce Y, Gao Y, Zhang WY, Neumeyer JL, Zubal IG, Charney DS, Hoffer PB, Innis RB. Whole-body biodistribution, radiation absorbed dose and brain SPECT imaging with iodine-123-β-CIT in healthy human subjects. J Nucl Med 1994; 35: 764-770.
24. Lamelle M, Wallace E, Seibyl JP. Graphical, kinetic and equilibrium analysis of the in vivo (123I)β-CIT binding to dopamine tranporters in healthy human subjects. J Cereb Blood Flow Metab 1994; 14: 982-994.
25. Kuikka JT, Bergström KA, Ahonen A, Länsimies E. The dosimetry of iodine-123 labelled 2-carbomethoxy-3-(4-iodophenyl)tropane. Eur J Nucl Med 1994; 21: 53-56.
26. van Dyck CH, Seibyl JP, Malison RT, Laruelle M, Wallace E, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Charney DS, Hoffer PB, Innis RB. Age-related decline in striatal dopamine transporter binding with iodine-123-β-CIT SPECT. J Nucl Med 1995; 36: 1175-1181.
27. 123I]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995; 38: 589-598.
28. 123I]β-CIT SPECT. Parkinsonism and Related Disorders 1995; 1: 47-51.
29. 123I]IPCIT as single-photon emission tomography radiotracers for the dopamine transporter in nonhuman primates. Eur J Nucl Med 1995; 22: 4-11.
30. Kuikka JT, Bergström KA, Ahonen A, Hiltunen J, Haukka J, Länsimies E, Wang S, Neumeyer JL. Comparison of iodine-123 labelled 2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and 2 beta-carbomethoxy-3 beta-(4-iodophenyl)-N-(3-fluoropropyl) nortropane for imaging of the dopamine transporter in the living human brain. Eur J Nucl Med 1995; 22: 356-360.
31. Kuikka JT, Akerman K, Bergström KA, Karhu J, Hiltunen J, Haukka J, Heikkinen J, Tiihonen J, Wang S, Neumeyer JL. Iodine-123 labelled N-(2-fluoroethyl)-2 beta-carbomethoxy-3 beta-(4-iodophenyl)nortropane for dopamine transporter imaging in the living human brain. Eur J Nucl Med 1995; 22: 682-686.
32. Kung M-P, Essmann WD, Frederick D, Meegalla S, Goodman M, Mu M, Lucki I, Kung HF. IPT: a novel iodinated ligand for the CNS dopamine transporter. Synapse 1995; 20: 316-324.
33. Abi-Dargham A, Gandelman MS, DeErausquin GA, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Laruelle M, Charney DS, Hoffer PB, Neumeyer JL, Innis RB. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of β-CIT. J Nucl Med 1996; 37: 1129-1133.
34. Malison RT, Vessotskie JM, Kung M-P, McElgin W, Romaniello G, Kim HJ, Goodman MM, Kung HF. Striatal dopamine transporter imaging in nonhuman primates with iodine-123-IPT SPECT. J Nucl Med 1995; 36: 2290-2297.
35. Mozley PD, Stubbs JB, Kim H-J, McElgin W, Kung M-P, Meegalla S, Kung HF. Dosimetry of an iodine-123-labeled tropane to image dopamine transporters. J Nucl Med 1996; 37: 151-159.
36. Mozley PD, Kim HJ, Gur RC, Tatsch K, Muenz LR, MeElgin WT, Kung M-P, Mu M, Myers AM, Kung HF. I-123 IPT SPECT imaging of CNS dopamine transporters: non-linear effects of normal aging on striatal uptake values. J Nucl Med 1996; 37: 1965-1970.
37. Donnan GA, Woodhouse DG, Kaczmarczyk SJ, Holder JE, Paxinos G, Chilco PJ, Churchyard AJ, Kalnins RM, Fabinyi GC, Mendelsohn FA. Evidence for plasticity of the dopaminergic system in parkinsonism. Mol Neurobiol 1991; 5: 421-433.
38. Kordower JH, Freeman TB, Snow BJ, Vingerhoets FJG, Mufson EJ, Sanberg PR, Hauser RA, Smith DA, Nauert GM, Perl DP, Olanow CW. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 1995; 332: 1118-1124.